On June 1, 2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, PhD, President and Chief Executive Officer of CytoDyn, Jacob Lalezari, MD, CEO of Quest Clinical Research and Chief Science Officer of CytoDyn, along with a representative of Amarex Clinical Research, the company’s CRO (contract research organization), will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Tuesday, June 2, 2020 at 12:30 pm EDT / 9:30 am PDT. The presentation will be approximately 15-20 minutes, followed by a Q&A session of approximately 30-40 minutes. Then event can be accessed at: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/. Interested participants are encouraged to login early prior to the start of the event, as the online event has a capacity of 3,000 participants. Please note that there will be no telephone access; this is a webcast-only event. The livestream presentation will be archived for 30 days. For anyone unable to attend live, a video will be posted on CytoDyn’s website approximately 24 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee. CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S., and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.Login Or Register To Read Full Story